Exploring Neurocrine Biosciences, Inc. (NBIX) Investor Profile: Who’s Buying and Why?

Exploring Neurocrine Biosciences, Inc. (NBIX) Investor Profile: Who’s Buying and Why?

US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ

Neurocrine Biosciences, Inc. (NBIX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Are you keeping a close watch on the biopharmaceutical sector, particularly companies making strides in neurological and endocrine-related disorders? Have you ever wondered who the major players are behind Neurocrine Biosciences, Inc. (NBIX), and what motivates their investment decisions? With a strong focus on innovative treatments and a growing portfolio, understanding the investor profile of Neurocrine Biosciences can provide valuable insights. In 2024, the company reported a revenue of $2.36 billion, marking a 24.81% increase from the previous year, and earnings of $341.30 million, a 36.68% increase. Let's delve into who is investing in NBIX and the factors driving their interest.

Neurocrine Biosciences, Inc. (NBIX) Who Invests in Neurocrine Biosciences, Inc. (NBIX) and Why?

Understanding the investor profile of Neurocrine Biosciences, Inc. (NBIX) involves examining the diverse range of individuals and institutions that hold its stock, as well as their motivations and strategies. This insight is crucial for current and prospective investors looking to align their investment approach with the broader market sentiment surrounding NBIX.

Key Investor Types:

The investor base of Neurocrine Biosciences, Inc. (NBIX) is composed of a mix of retail investors, institutional investors, and hedge funds. Each group has different investment horizons, risk tolerances, and objectives, which collectively influence the stock's trading dynamics.

  • Retail Investors: These are individual investors who buy and sell shares for their own accounts. Their investment decisions are often based on personal research, recommendations from financial advisors, and market news.
  • Institutional Investors: These include mutual funds, pension funds, insurance companies, and endowments that manage large sums of money on behalf of others. Institutional investors typically conduct in-depth research and analysis before making investment decisions and often hold stocks for the long term.
  • Hedge Funds: These are investment partnerships that use a variety of strategies, including leverage, derivatives, and short selling, to generate high returns. Hedge funds tend to have a shorter investment horizon and are more actively involved in trading than institutional investors.

As of December 31, 2024, the top institutional holders of Neurocrine Biosciences, Inc. (NBIX) included:

  • Vanguard Group Inc.
  • BlackRock Fund Advisors
  • State Street Global Advisors Inc.

Investment Motivations:

Investors are attracted to Neurocrine Biosciences, Inc. (NBIX) for a variety of reasons, primarily related to its growth prospects, market position, and potential for innovation in the biopharmaceutical industry.

  • Growth Prospects: Neurocrine Biosciences, Inc. (NBIX) is a biotechnology company focused on neurological, endocrine and psychiatric disorders. Investors are drawn to Neurocrine Biosciences, Inc. (NBIX)'s potential for future revenue and earnings growth, driven by the development and commercialization of new therapies.
  • Market Position: Neurocrine Biosciences, Inc. (NBIX)'s established presence in the market, particularly with its FDA-approved treatments, enhances its appeal to investors. A strong market position often translates to a competitive advantage and sustainable revenue streams.

Investment Strategies:

The investment strategies employed by Neurocrine Biosciences, Inc. (NBIX) investors vary depending on their investment goals and risk tolerance.

  • Long-Term Holding: Many institutional investors adopt a long-term holding strategy, focusing on the company's long-term growth potential and ability to generate value over time. This strategy involves holding shares for an extended period, often several years, to benefit from the company's growth and potential capital appreciation.
  • Short-Term Trading: Hedge funds and some retail investors may engage in short-term trading strategies, seeking to profit from short-term price fluctuations in Neurocrine Biosciences, Inc. (NBIX)'s stock. These strategies involve frequent buying and selling of shares to capitalize on market volatility.
  • Value Investing: Some investors may view Neurocrine Biosciences, Inc. (NBIX) as a value investment, believing that the stock is undervalued by the market and has the potential to appreciate in value over time. Value investors typically look for companies with strong fundamentals, such as solid financial performance and a sustainable competitive advantage.

Understanding the composition, motivations, and strategies of Neurocrine Biosciences, Inc. (NBIX)'s investor base provides valuable insights into the market dynamics and sentiment surrounding the stock. This knowledge can help investors make informed decisions and align their investment approach with the broader market trends.

Explore more about Neurocrine Biosciences, Inc. (NBIX): Mission Statement, Vision, & Core Values of Neurocrine Biosciences, Inc. (NBIX).

Neurocrine Biosciences, Inc. (NBIX) Institutional Ownership and Major Shareholders of Neurocrine Biosciences, Inc. (NBIX)

Understanding the institutional ownership of Neurocrine Biosciences, Inc. (NBIX) can offer valuable insights into the company’s stock price and overall strategy. Institutional investors, who manage large sums of money, often have a significant impact on a company's performance due to the size of their holdings and their investment strategies.

Top Institutional Investors

Here are some of the top institutional investors in Neurocrine Biosciences, Inc. (NBIX), along with their shareholdings:

  • Vanguard Group Inc.: As of March 31, 2024, Vanguard Group Inc. holds 9,584,822 shares, representing about 9.77% of the company.
  • BlackRock Fund Advisors: According to the data from March 31, 2024, BlackRock Fund Advisors owns 7,969,787 shares, which accounts for approximately 8.13% of the company.
  • State Street Global Advisors, Inc.: The data from March 31, 2024 shows that State Street Global Advisors, Inc. possesses 4,073,490 shares, holding around 4.16% of the company.
  • Geode Capital Management, LLC: Geode Capital Management, LLC’s filings from March 31, 2024, indicate they possess 2,037,891 shares, or about 2.08% of the company.
  • FMR LLC: According to the March 31, 2024, FMR LLC holds 1,914,029 shares, representing approximately 1.95% of the company.

Changes in Ownership

Institutional investors frequently adjust their holdings based on their outlook on the company's future and broader market conditions. Recent changes in ownership can be indicative of investor sentiment.

For instance:

  • The Vanguard Group increased its stake by 1.3% in the first quarter of 2024.
  • BlackRock Fund Advisors decreased its stake by 1.2% in the first quarter of 2024.

These changes, while seemingly small, can reflect significant shifts in investor confidence and strategy.

Impact of Institutional Investors

Institutional investors play a crucial role in Neurocrine Biosciences, Inc. (NBIX)’s stock price and strategy:

  • Price Stability: Large institutional holdings can provide a degree of stability to the stock price, as these investors tend to have a long-term investment horizon.
  • Influence on Strategy: Significant shareholders often engage with company management, influencing strategic decisions and corporate governance.
  • Market Perception: The actions of major institutional investors are closely watched by other market participants, impacting overall market perception of the company.

Here is a detailed look at the institutional ownership of Neurocrine Biosciences, Inc. (NBIX) based on recent filings:

Investor Shares Held (2024-03-31) % of Shares Outstanding
Vanguard Group Inc. 9,584,822 9.77%
BlackRock Fund Advisors 7,969,787 8.13%
State Street Global Advisors, Inc. 4,073,490 4.16%
Geode Capital Management, LLC 2,037,891 2.08%
FMR LLC 1,914,029 1.95%

Understanding these ownership dynamics is essential for investors looking to gain a comprehensive view of Neurocrine Biosciences, Inc. (NBIX). For further insights into the company's financial standing, consider exploring: Breaking Down Neurocrine Biosciences, Inc. (NBIX) Financial Health: Key Insights for Investors

Neurocrine Biosciences, Inc. (NBIX) Key Investors and Their Impact on Neurocrine Biosciences, Inc. (NBIX)

Understanding the investor profile of Neurocrine Biosciences, Inc. (NBIX) provides valuable insights into the company's stability, growth potential, and strategic direction. Examining who is investing and their motivations can reveal a great deal about market sentiment and future expectations for the company.

Institutional investors form a significant portion of Neurocrine Biosciences, Inc. (NBIX)'s shareholder base. These entities often include mutual funds, pension funds, hedge funds, and insurance companies. Their investment decisions are driven by in-depth research and analysis, reflecting their confidence in the company's long-term prospects. According to the latest available data, institutional ownership represents a substantial percentage of Neurocrine Biosciences, Inc. (NBIX)'s outstanding shares.

Here are some of the notable institutional investors in Neurocrine Biosciences, Inc. (NBIX):

  • Vanguard Group: Often holds a significant stake, reflecting its investment strategy in the biotechnology sector.
  • BlackRock Fund Advisors: Another major institutional holder, with substantial investments across various sectors, including healthcare.
  • State Street Corporation: Known for its diverse investment portfolio, with a notable position in Neurocrine Biosciences, Inc. (NBIX).
  • FMR (Fidelity Management & Research): A large asset manager showing continued interest in Neurocrine Biosciences, Inc. (NBIX).

These major investors can exert considerable influence on Neurocrine Biosciences, Inc. (NBIX)'s stock performance and strategic decisions. Their actions, such as increasing or decreasing their positions, can send signals to the market, impacting stock prices and investor confidence. For example, a large purchase by a well-known fund can lead to increased investor interest and a potential rise in stock value. Conversely, a significant sell-off might trigger concerns and a decline in price.

Recent moves by institutional investors are closely watched by analysts and individual investors alike. Monitoring these activities can provide clues about the perceived value and future direction of Neurocrine Biosciences, Inc. (NBIX). Significant increases in holdings by major institutions often indicate a positive outlook, while substantial reductions may suggest potential risks or concerns. These moves are usually disclosed in regulatory filings, such as 13F filings, which provide a quarterly snapshot of institutional investment positions.

The influence of these investors extends to corporate governance. Large institutional shareholders often engage with company management to discuss strategy, performance, and governance issues. Their voting power can impact decisions on executive compensation, board appointments, and significant corporate actions. Activist investors, who take large positions with the goal of influencing company policy, can also play a role in shaping Neurocrine Biosciences, Inc. (NBIX)'s direction.

Understanding the composition and behavior of Neurocrine Biosciences, Inc. (NBIX)'s investor base is crucial for anyone looking to invest in or follow the company. It provides a deeper understanding of the factors driving stock performance and the potential challenges and opportunities facing the company.

Below is a hypothetical example of Neurocrine Biosciences, Inc. (NBIX)'s major shareholders and their estimated holdings based on available data:

Shareholder Type Ownership Percentage (approximation)
Vanguard Group Investment Management Company 11.9%
BlackRock Fund Advisors Investment Management Company 7.7%
State Street Corporation Financial Services 4.0%
FMR (Fidelity Management & Research) Investment Management Company 3.1%

Keep in mind that ownership percentages can fluctuate as investors buy and sell shares. It is important to consult the most recent filings and financial news for up-to-date information.

For more information, you might find this resource helpful: Neurocrine Biosciences, Inc. (NBIX): History, Ownership, Mission, How It Works & Makes Money

Neurocrine Biosciences, Inc. (NBIX) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of Neurocrine Biosciences, Inc. (NBIX). Recent analyst ratings, ownership structures, and market trends offer valuable insights into the company's current standing and future prospects.

Here’s an overview of the key factors influencing Neurocrine Biosciences' market dynamics:

  • Investor Sentiment: Currently, investor sentiment appears to be positive, driven by factors such as positive FDA news, promising clinical trial results, and strategic partnerships.
  • Market Reaction: The stock market has generally responded favorably to these developments, with Neurocrine Biosciences' stock trading up by as much as 3.72% following positive clinical trial results and FDA news.
  • Analyst Perspectives: Analysts at firms like Needham and RBC Capital have upgraded Neurocrine Biosciences, citing optimistic projections and strong franchise performance, particularly the Ingrezza franchise.

Neurocrine Biosciences has been in the spotlight due to key developments that have positively influenced its stock performance. The company's stock has shown a steady upward trend, driven by:

  • Positive outcomes from Phase 3 clinical trials for its lead drug candidate.
  • Strategic partnerships aimed at expanding its pipeline and market reach.
  • Proactive communication from the management team regarding the company's long-term vision and commitment to shareholder value.

The surge in trading volume, reaching $316 million on April 16, 2025, an 86.54% increase from the previous day, underscores heightened investor interest.

Several financial metrics reflect Neurocrine Biosciences' robust financial health:

  • Gross Margin: An impressive 98.6%, highlighting efficient production and cost management.
  • Return on Equity (ROE): Approximately 14%, demonstrating the company's ability to generate profit from its equity base.
  • Return on Assets (ROA): Solid at 9.37%.
  • Debt-to-Equity Ratio: A nimble 0.18, indicating less reliance on debt financing.
  • Current Ratio: An impressive 3.4, suggesting a secure position to cover short-term liabilities with its present assets.

Analysts' evaluations of 12-month price targets provide additional insights, showcasing an average target of $165.44, with a high estimate of $185.00 and a low estimate of $137.00. However, the current average is 3.59% lower than the prior average price target of $171.60.

Here is a summary of analyst ratings for Neurocrine Biosciences:

Rating Count
Strong Buy Approximately 39%
Buy Approximately 42%
Hold Approximately 18%
Sell 0%
Strong Sell 0%

The consensus rating for Neurocrine Biosciences is 'Buy,' based on evaluations from 33 analysts. The average analyst price target in the past 3 months is $156.40.

Major shareholders of Neurocrine Biosciences include:

  • BlackRock Advisors LLC: Holding 12.68% (12,641,134 shares)
  • The Vanguard Group, Inc.: Holding 10.16% (10,129,687 shares)
  • Vanguard Fiduciary Trust Co.: Holding 10.15% (10,119,641 shares)
  • STATE STREET CORPORATION: Holding 4.906% (4,891,137 shares)
  • Dodge & Cox: Holding 3.025% (3,016,425 shares)

Institutional investors own approximately 55.47% of Neurocrine Biosciences' stock, while insiders own about 1.09%, and public companies and individual investors hold around 43.44%.

For more insights into Neurocrine Biosciences' mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Neurocrine Biosciences, Inc. (NBIX).

DCF model

Neurocrine Biosciences, Inc. (NBIX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.